Alumis Announces Pricing of Upsized Public Offering of Common Stock

Rhea-AI Summary

Alumis (Nasdaq: ALMS) priced an upsized underwritten public offering of 17,650,000 shares at $17.00 per share, generating approximately $300.0 million in gross proceeds before fees. The company is selling all shares and granted the underwriters a 30-day option to buy up to an additional 2,647,500 shares at the public offering price, less discounts and commissions. The offering is expected to close on January 9, 2026, subject to customary closing conditions. The offering is being conducted under an SEC-declared effective shelf registration and will be documented in a final prospectus filed with the SEC.

Positive

• Gross proceeds of approximately $300.0 million
• Offering fully primary — all shares sold by company
• Underwriters granted only a 30-day option for 2,647,500 shares

Negative

• Issuance of 17,650,000 shares will dilute existing shareholders
• Underwriting discounts and expenses will reduce net proceeds
• Potential short-term downward pressure on stock around the close

News Market Reaction – ALMS

+1.45% 1.8x vol

32 alerts

+1.45% Session close to close

+11.8% Peak in 26 hr 32 min

$1.98B Market Cap

1.8x Rel. Volume

In the Jan 8 session, ALMS gained 1.45%, reflecting a mild positive market reaction. Argus tracked a peak move of +11.8% during that session. Our momentum scanner triggered 32 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement prices an upsized underwritten public offering of 17,650,000 shares at $17.00, for...

Analysis

This announcement prices an upsized underwritten public offering of 17,650,000 shares at $17.00, for expected gross proceeds of $300.0 million, plus a 30-day option on additional shares. The deal comes shortly after strong Phase 3 data and an earlier proposed offering. Historically, offering headlines have coincided with large moves, while earnings and conference updates had modest impact. Investors may focus on use of proceeds, execution of the psoriasis program, and any future draws under the existing Form S-3 shelf.

Key Figures

Shares offered: 17,650,000 shares Offering price: $17.00 per share Gross proceeds: $300.0 million +5 more

8 metrics

Shares offered 17,650,000 shares Upsized underwritten public offering of common stock

Offering price $17.00 per share Public offering pricing for common stock

Gross proceeds $300.0 million Expected gross proceeds before discounts and expenses

Underwriters’ option shares 2,647,500 shares 30-day option to purchase additional common stock

Option period 30 days Underwriters’ option duration for additional shares

Offering close date January 9, 2026 Expected closing date subject to customary conditions

Shelf effectiveness date August 19, 2025 Form S-3 shelf registration declared effective by SEC

Pre-news price change 10.41% Move in ALMS prior to pricing announcement

Historical Context

5 past events · Latest: Jan 06 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 06	Equity offering plan	Negative	+95.3%	Announced proposed common stock offering with underwriter option and set managers.
Jan 06	Phase 3 results	Positive	+95.3%	Reported positive Phase 3 envudeucitinib psoriasis data with strong skin clearance.
Jan 05	Data call notice	Neutral	-7.2%	Announced conference call and webcast to present ONWARD Phase 3 topline data.
Nov 13	Q3 2025 earnings	Neutral	+0.8%	Released Q3 2025 financials with cash runway into 2027 and clinical milestones.
Nov 04	Investor conferences	Neutral	-0.2%	Outlined participation in November healthcare investor conferences and webcasts.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive clinical and earnings updates have seen generally aligned reactions, while offering-related headlines have coincided with unusually strong upside moves, indicating a tendency for divergence around financing events.

Recent Company History

Over recent months, Alumis reported Q3 2025 results on Nov 13, 2025 with substantial R&D investment and adequate funding into 2027. The stock reacted modestly (0.76%). Subsequent conference participation in early November had minimal impact. In early January 2026, the company released highly positive Phase 3 data for envudeucitinib with a 95.31% move, followed by a proposed offering announcement, also linked to a strong price rise. Today’s upsized offering pricing follows this sequence of value-creating clinical news and rapid equity financing activity.

Key Terms

underwritten public offering, gross proceeds, underwriting discounts and commissions, prospectus supplement, +4 more

8 terms

underwritten public offering financial

"announced the pricing of an upsized underwritten public offering of 17,650,000 shares"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

gross proceeds financial

"The gross proceeds to Alumis from the offering, before deducting underwriting discounts"

The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.

underwriting discounts and commissions financial

"before deducting underwriting discounts and commissions and offering expenses"

Underwriting discounts and commissions are fees paid to financial institutions that help sell new securities to investors. They act like a commission for their role in connecting companies with buyers, often reducing the amount of money the issuing company raises. For investors, understanding these costs helps gauge how much of their investment is going toward the actual securities versus fees paid to middlemen.

prospectus supplement regulatory

"A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

shelf registration statement regulatory

"The public offering is being made pursuant to a shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"shelf registration statement on Form S-3, including a base prospectus, that was previously filed"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

base prospectus regulatory

"on Form S-3, including a base prospectus, that was previously filed with the Securities"

A base prospectus is a detailed document that provides essential information about a financial offering, such as a bond or share issue. It acts like a comprehensive guide for investors, explaining what the investment involves, the risks involved, and how the process works. This helps investors make informed decisions before committing their money.

book-running managers financial

"Morgan Stanley, Leerink Partners, Cantor and Wells Fargo Securities are acting as joint book-running managers"

Book-running managers are the main banks or financial firms that organize and oversee a company's sale of new stocks or bonds. They help set the price, decide how many to sell, and coordinate the process to make sure everything runs smoothly. Their role is important because they guide the company through the complex process of raising money from investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the pricing of an upsized underwritten public offering of 17,650,000 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds to Alumis from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $300.0 million. All shares in the offering are being sold by Alumis. The offering is expected to close on January 9, 2026, subject to the satisfaction of customary closing conditions.

In addition, Alumis has granted the underwriters a 30-day option to purchase up to an additional 2,647,500 shares of common stock at the public offering price, less underwriting discounts and commissions.

Morgan Stanley, Leerink Partners, Cantor and Wells Fargo Securities are acting as joint book-running managers for the offering. Baird and Oppenheimer & Co. are acting as co-lead managers for the offering. 

The public offering is being made pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on August 19, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering were filed with the SEC and are available for free on the SEC’s website located at http://www.sec.gov. A final prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available for free on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at (866) 718-1649, or by email at prospectus@morganstanley.com; Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com; or Wells Fargo Securities, LLC, Attention: Wells Fargo Securities, 90 South 7th Street, 5th Floor, Minneapolis, MN 55402, at 800-645-3751 (option #5) or email a request to WFScustomerservice@wellsfargo.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Alumis

Alumis is a clinical-stage biopharmaceutical company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib (or envu, formerly known as ESK-001) for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, the pipeline includes lonigutamab, a subcutaneously delivered anti–insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.

Alumis Contact Information 
Teri Dahlman 
Red House Communications 
teri@redhousecomms.com

FAQ

How many shares did Alumis (ALMS) offer in the upsized public offering?

Alumis offered 17,650,000 shares of common stock at $17.00 per share.

How much gross proceeds will Alumis (ALMS) raise from the offering?

The offering is expected to generate approximately $300.0 million in gross proceeds before underwriting discounts and commissions.

When is the Alumis (ALMS) offering expected to close?

The offering is expected to close on January 9, 2026, subject to customary closing conditions.

Does Alumis (ALMS) grant the underwriters any overallotment option?

Yes — the underwriters have a 30-day option to purchase up to 2,647,500 additional shares at the offering price, less discounts and commissions.

Will the Alumis (ALMS) offering include secondary shares from insiders?

No — all 17,650,000 shares in the offering are being sold by Alumis (primary issuance).

Where can investors find the final prospectus for the Alumis (ALMS) offering?

The final prospectus will be filed with the SEC and available for free on www.sec.gov once posted.